Search

Your search keyword '"Ellin Berman"' showing total 118 results

Search Constraints

Start Over You searched for: Author "Ellin Berman" Remove constraint Author: "Ellin Berman"
118 results on '"Ellin Berman"'

Search Results

1. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

2. Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

3. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

5. Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

6. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification

7. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

9. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

10. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

11. How I treat chronic-phase chronic myelogenous leukemia

12. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

13. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study

14. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

15. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy

16. CML-089: Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia

17. Gilteritinib or Chemotherapy for Relapsed or Refractory

18. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 35INS

19. An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia

20. Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up

21. Reply to D.M. Ross et al and V. Florou et al

22. Pregnancy in Patients With Chronic Myeloid Leukemia

23. Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy

24. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

25. S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

26. Reply to N. Cerveira et al

27. Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia

28. Where Exactly Does Ponatinib Fit in Chronic Myelogenous Leukemia?

29. Leukemogenesis Induced by an Activating β-catenin mutation in Osteoblasts

30. Role of Consolidation Therapy Prior to CD34− Selected Allogeneic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First Remission

31. Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

32. Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

33. Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial

34. PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO-MUTATIONS OR A HIGH FLT3-ITD ALLELIC RATIO

35. Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio

36. Chronic Myelogenous Leukemia, Version 1.2014

37. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors

38. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization

39. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017

40. Genetic mutations in chronic myelogenous leukemia

41. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

42. Chronic Myelogenous Leukemia

43. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease

44. Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation

45. Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

46. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

47. Recent advances in the treatment of acute leukemia: 1999

48. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

49. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

50. Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia

Catalog

Books, media, physical & digital resources